Anticancer agent 230

• Description:

  Anticancer agent 230 (example 65) is a caseinolytic protease P (ClpP) activator with anticancer activity. Anticancer agent 230 is able to induce the degradation of mitochondrial proteins in SUM159 and MDA-MB-231 triple-negative breast cancer cells in a time-dependent manner[1].

• UNSPSC:

  12352005

• Target:

  ClpP

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/anticancer-agent-230.html

• Purity:

  99.97

• Solubility:

  DMSO : 50 mg/mL (ultrasonic)

• Smiles:

  N#CC1=CC=CC(CN(C2)CCC(N=CN3CC4=CC=C(Cl)C=C4)=C2C3=O)=C1

• Molecular Formula:

  C22H19ClN4O

• Molecular Weight:

  390.87

• References & Citations:

  [1]Preparation of tetrahydropyrido[4,3-d]pyrimidine-2,4-dione analogs useful in the treatment of cancers and in modulating the activity of caseinolytic protease p function. United States, US20230339947 A1. 2023-10-26.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [2485052-87-5]